VenoVision was selected to participate in the MassChallenge 2023 HealthTech Sprint. It was one of over 200 startup applications for this year’s program.
VenoVision provides the missing non-invasive cardiological data and monitoring needed to reduce ICU admissions and hospitalizations for millions of heart failure and at-risk patients. VenoVision is a low cost, easy-to-use, imaging device and hemodynamic monitoring platform for the inpatient, outpatient and home settings.
By participating in this accelerator, VenoVision will receive unrivaled access to a global network of partners, experts, and mentors. Throughout the program, the company will join 37 startups who will benefit from integration into healthcare ecosystems through MassChallenge partnerships, as well as Medicare and Medicaid curriculum by MITRE to support federal opportunities.
“VenoVision is proud to continue its development in the MassChallenge community, having made the transition from MassChallenge Israel 2021 Finalist to Delaware C-Corp, as part of the Health Wildcatters Accelerator in Dallas, and now participating in the MassChallenge HealthTech Sprint in the USA.” – Jonathan Maron, President, VenoVision.
VenoVision will be working with MassChallenge to establish partnerships across clinical, regulatory and reimbursement pathways.
To read more, click here.
Cora Therapeutics, a Toronto-based life sciences start-up, has raised $1 million in seed funding. It’s the closure of the second round of seed funding and Irongate Capital Advisors led the round. The company has raised $1.8 million of seed funding to date.
Led by Dr. Kieran Murphy, Cora Therapeutics, develops research-based solutions for whole body health. DNA HALO is a powerful formulation of antioxidants protecting cellular and mitochondrial DNA from nuclear and medical radiation. It is a patented blend of ingredients from natural sources, compliant with strict U.S. and Canadian regulatory bodies. The formulation has been optimized for over a decade within leading institutions and currently has four issued patents globally. Six clinical papers have been published in peer reviewed journals validating the work driven out of collaborations with Dalhousie University, University of Toronto, and McMaster University.
Cora Therapeutics will use the funds to fuel the launch of DNA HALO in North America. They will be targeting medical professionals, medical imaging patients, air travel professionals, frequent fliers, military personnel, and the health-conscious public.
Zorro, which optimizes health benefits experience for employees, employers and brokers, has emerged out of stealth, with a $11.5 million seed funding round co-led by Pitango and 10D. The funds will be used to further expand R&D efforts and scale customer operations.
Zorro analyzes employers’ benefit objectives to create a top-down predictable budget and benefit allowance per employee or group of employees. It also provides an end-to-end insurance management solution that offers a single, comprehensive platform making administering benefits seamless and effective.
Guy Ezekiel, CEO and co-founder of Zorro said:
“Our solution flips the outdated health benefits model upside down and gives employers predictability, while providing employees with the coverage that best fits their needs. The multi-disciplinary expertise that exists among the Zorro team members, including in healthcare, insuretech, software and big data, is a unique asset that allows us to accomplish our important mission of improving access to quality and affordable healthcare.”
To learn more, click here.
Validic Inc., a digital health and personalized care company, has expanded its Internet of Things platform with the integration of Smart Meter. This integration brings exclusive cellular-enabled, patient-friendly monitoring devices supplied by Smart Meter, a leading connected health solution supplier to a rapidly growing nationwide network of SmartPartners, to the Validic ecosystem, according to a press release.
Smart Meter’s FDA-registered monitoring devices are connected to an exclusive AT&T 4/5G private data network to ensure an engaging patient experience for improved adherence, according to the press release. The devices help manage the most prevalent chronic conditions, including blood glucose monitors for diabetes; blood pressure monitors for hypertension and other cardiac diseases; pulse oximeters for COPD, Covid-19, and other respiratory disorders; and weight scales for congestive heart failure and weight-related diseases.
Validic CEO Drew Schiller said: “The addition of Smart Meter cellular-enabled health monitoring devices to our ecosystem offers another option to help people focus on their health and live their best lives.”
To read more, click here.
Picture: akindo, Getty Images
This is a paid member feature of MedCitizens. Please submit here and join!